Physician profile
Gregory Blair
NPI 1598731291
$7,460.42
in general payments reported to CMS, 2019-2025
58 companies · $1,374 in 2025
The $1,374 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,713 · 2020: $278 · 2021: $555 · 2022: $1,315 · 2023: $1,294 · 2024: $931 · 2025: $1,374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,202 · Long Term Medical Supply Or Device Loan: $299 · Education: $98.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,201.66 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $98.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $910.13 | 2019-2025 | |
| Genentech USA, INC. | $843.55 | 2019-2025 | Polivy, Tecentriq, Itovebi |
| E.R. Squibb & Sons, L.L.C. | $585.68 | 2019-2025 | Opdualag, Opdivo |
| Astrazeneca Pharmaceuticals LP | $408.50 | 2019-2025 | Lynparza, Enhertu |
| Merck Sharp & Dohme LLC | $397.88 | 2019-2025 | Keytruda, Welireg |
| Astellas Pharma US INC | $377.13 | 2019-2025 | Xtandi, Vyloy, Padcev |
| Pfizer INC. | $374.31 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $336.20 | 2021-2025 | Libtayo |
| Amgen INC. | $289.31 | 2019-2022 | |
| Eisai INC. | $223.60 | 2019-2025 | |
| Janssen Biotech, INC. | $223.59 | 2019-2025 | Rybrevant, Imbruvica |
| Abbvie INC. | $193.47 | 2019-2025 | Venclexta |
| Incyte Corporation | $184.71 | 2022-2025 | Monjuvi, Zynyz, Pemazyre |
| Daiichi Sankyo INC. | $134.96 | 2021-2025 | Enhertu, Datroway |
| Genzyme Corporation | $132.64 | 2019-2025 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Blair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.